Written questions by Stafford.

How many NHS trusts in England provide specialist clinics for Ehlers–Danlos syndrome.

Integrated care boards (ICBs) have a statutory responsibility to commission services which meet the needs of their local population, including for those with Ehlers-Danlos syndrome (EDS). It is the responsibility of ICBs, working with clinicians, service users, and patient groups, to develop services and care pathways that meet patients’ needs.More widely, through the 10-Year Health Plan, we are introducing Neighbourhood Health Centres, and deploying multidisciplinary teams to provide holistic support to people with EDS. Patients will benefit from enhanced NHS App functionality, including the My Medicines and My Health sections, and will be able to self-refer to specialist services where appropriate.Additionally, the 10-Year Health Plan’s commitments on artificial intelligence will give clinicians advanced tools for faster diagnosis, predictive analytics, and personalised care planning. For people with long-term conditions like EDS, this means earlier interventions, better monitoring of complex needs, and more time for clinicians to focus on patient-centred care rather than administrative tasks. The plan also commits to 95% of people with complex needs having a personalised care plan by 2027.

What steps her Department is taking to reduce the time taken for (a) referrals and (b) assessments for Ehlers-Danlos syndrome.

The Department recognises that Ehlers-Danlos syndromes (EDS) are complex, multi-systemic conditions that can be challenging to diagnose. While no formal assessment of average diagnosis times has been made, the Department is aware that many patients experience significant delays for a confirmed diagnosis. These delays are primarily due to low awareness among clinicians, the absence of a single diagnostic test for hypermobile EDS, and the need for multidisciplinary input.For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service. In addition to investigating and diagnosing complex and rare EDS types, the national diagnostic service supports general practitioners (GPs) and specialists in secondary and tertiary care by issuing detailed reports with management recommendations, developing guidelines and pathways of care, and offering clinician-to-clinician advice. It helps GPs by clarifying referral pathways and guiding ongoing care, while supporting hospital specialists through access to genetic testing, multidisciplinary input, and best practice guidance. This collaboration ensures accurate diagnosis, reduces unnecessary investigations, and promotes coordinated care across all levels of the health system, helping to avoid inappropriate referrals and ensuring that patients are able to access the correct specialist care efficiently.We also recognise that GPs can find it challenging to diagnose EDS because these conditions share symptoms with many other disorders. The EDS GP Toolkit, developed by the Royal College of General Practitioners in partnership with Ehlers-Danlos Support UK, helps GPs in managing EDS by improving recognition, diagnosis, and management of these multi-system disorders. The toolkit aims to reduce delays in diagnosis and helps to prevent long-term disability through appropriate early management.The Department is engaging with patient organisations to identify further opportunities to streamline referral processes and ensure equitable access to assessment and care.

What recent assessment she has made of the adequacy of NHS waiting times for the diagnosis of Ehlers–Danlos syndrome.

The Department recognises that Ehlers-Danlos syndromes (EDS) are complex, multi-systemic conditions that can be challenging to diagnose. While no formal assessment of average diagnosis times has been made, the Department is aware that many patients experience significant delays for a confirmed diagnosis. These delays are primarily due to low awareness among clinicians, the absence of a single diagnostic test for hypermobile EDS, and the need for multidisciplinary input.For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service. In addition to investigating and diagnosing complex and rare EDS types, the national diagnostic service supports general practitioners (GPs) and specialists in secondary and tertiary care by issuing detailed reports with management recommendations, developing guidelines and pathways of care, and offering clinician-to-clinician advice. It helps GPs by clarifying referral pathways and guiding ongoing care, while supporting hospital specialists through access to genetic testing, multidisciplinary input, and best practice guidance. This collaboration ensures accurate diagnosis, reduces unnecessary investigations, and promotes coordinated care across all levels of the health system, helping to avoid inappropriate referrals and ensuring that patients are able to access the correct specialist care efficiently.We also recognise that GPs can find it challenging to diagnose EDS because these conditions share symptoms with many other disorders. The EDS GP Toolkit, developed by the Royal College of General Practitioners in partnership with Ehlers-Danlos Support UK, helps GPs in managing EDS by improving recognition, diagnosis, and management of these multi-system disorders. The toolkit aims to reduce delays in diagnosis and helps to prevent long-term disability through appropriate early management.The Department is engaging with patient organisations to identify further opportunities to streamline referral processes and ensure equitable access to assessment and care.

What plans her Department has to improve training and clinical awareness of Ehlers–Danlos syndrome among GPs and primary care clinicians to support earlier recognition and referral.

The Department recognises that Ehlers-Danlos syndromes (EDS) are complex, multi-systemic conditions that can be challenging to diagnose. While no formal assessment of average diagnosis times has been made, the Department is aware that many patients experience significant delays for a confirmed diagnosis. These delays are primarily due to low awareness among clinicians, the absence of a single diagnostic test for hypermobile EDS, and the need for multidisciplinary input.For rarer genetically confirmed types of EDS, NHS England commissions a national diagnostic service. In addition to investigating and diagnosing complex and rare EDS types, the national diagnostic service supports general practitioners (GPs) and specialists in secondary and tertiary care by issuing detailed reports with management recommendations, developing guidelines and pathways of care, and offering clinician-to-clinician advice. It helps GPs by clarifying referral pathways and guiding ongoing care, while supporting hospital specialists through access to genetic testing, multidisciplinary input, and best practice guidance. This collaboration ensures accurate diagnosis, reduces unnecessary investigations, and promotes coordinated care across all levels of the health system, helping to avoid inappropriate referrals and ensuring that patients are able to access the correct specialist care efficiently.We also recognise that GPs can find it challenging to diagnose EDS because these conditions share symptoms with many other disorders. The EDS GP Toolkit, developed by the Royal College of General Practitioners in partnership with Ehlers-Danlos Support UK, helps GPs in managing EDS by improving recognition, diagnosis, and management of these multi-system disorders. The toolkit aims to reduce delays in diagnosis and helps to prevent long-term disability through appropriate early management.The Department is engaging with patient organisations to identify further opportunities to streamline referral processes and ensure equitable access to assessment and care.

What steps his Department is taking to ensure continuity and improvement of national cancer awareness campaigns following the abolition of NHS England, including plans to raise awareness of the symptoms of gynaecological cancers and support earlier diagnosis of ovarian cancer.

Early diagnosis of cancer remains a key priority for the Government. The Government will continue to work to ensure that the public is aware of cancer symptoms, especially for cancers such as ovarian cancer, which are harder to detect in the early stages.We will work to ensure a smooth transition during the merger of NHS England and the Department, so that the public continues to have access to high-quality cancer care.

What discussions the Government has had with representatives of the United States on the pricing of medicines for the NHS in the last six months.

The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people to access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.Thanks to the strength of our relationship with the United States, we have secured the first and only deal with them that delivers 0% tariffs on pharmaceutical products, the lowest rate offered to any country. This deal secures the United Kingdom’s access to and supply of medicines for tens of thousands of patients while safeguarding our supply chain and ensuring groundbreaking new treatments will reach the NHS front line quicker. It also delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK MedTech exports, helping expand access innovative treatments for patients and driving crucial investment in the UK.

What assessment his Department has made of the current strategic approach to ME/CFS research; and whether his Department plans to develop a coordinated national research strategy for the condition.

We have outlined our strategy to support myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), research in the ME/CFS Final Delivery Plan published in July. These steps include a research showcase event, a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions, and the announcement of new funded studies in health and care services, and research infrastructure and capacity-building.We are determined to accelerate progress in the treatment and management of ME/CFS and will continue working with the ME/CFS community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes.The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

What assessment his Department has made of the adequacy of the availability of ADHD medication.

The Department has made substantial progress in improving the availability of medicines for attention deficit hyperactivity disorder (ADHD), working closely with industry and key stakeholders to resolve previous supply challenges. Through intensive work with industry, NHS England and the Medicines and Healthcare products Regulatory Agency have resolved most of the previous shortages. All strengths of lisdexamfetamine, atomoxetine, both the capsules and the oral solution, guanfacine prolonged-release tablets, and methylphenidate prolonged-release tablets are now available.There is a current supply issue with methylphenidate 30 milligram prolonged-release capsules, brand name Equasym XL, which is out of stock until late December. The Department has issued guidance to healthcare professionals with advice on how to manage patients until this shortage resolves.We continue to work closely with suppliers to resolve the few remaining challenges and to strengthen resilience in the supply chain. This includes securing additional stocks, expediting deliveries, and expanding the United Kingdom supplier base to support future demand. In collaboration with NHS England’s ADHD taskforce and national data improvement plan, we are developing growth forecasts to improve demand planning and ensure a sustainable supply of ADHD medicines.To support prescribers and dispensers, the Department maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, at the following link:www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd

What steps he is taking to help reduce waiting times for ADHD medication.

It is the responsibility of integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including providing access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence guidelines.NHS England established an ADHD taskforce which brought together those with lived experience with experts from the National Health Service, education, charity, and justice sectors to get a better understanding of the challenges affecting those with ADHD, including in accessing timely and equitable access to services and support. We are pleased that the taskforce's final report was published in November 2025, and we are carefully considering its recommendations.For the first time, NHS England published management information on ADHD waits at a national level on 29 May 2025 as part of its ADHD data improvement plan; it will soon release technical guidance to ICBs to improve recording of ADHD data, with a view to improving the quality of ADHD waits data. NHS England has also captured examples from ICBs who are trialling innovative ways of delivering ADHD services and is using this information to support systems to tackle ADHD waiting lists and provide support to address people’s needs.My rt. Hon. Friend, the Secretary of State for Health and Social Care, announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. This independent review will inform our approach to enabling people with ADHD and autistic people to have the right support to enable them to live well in their communities.

What assessment his Department has made of the potential impact of the early flu season on corridor care, hospital capacity and patient outcomes.

We continue to monitor the impact of flu and the performance of hospitals over the winter months.The Department is continuing to take key steps to ensure the health service is prepared for the colder months. This includes taking actions to try and reduce demand pressure on accident and emergency, increasing vaccination rates, and offering health checks to the most vulnerable, as well as stress-testing integrated care boards and trust winter plans to ensure that they are able to meet demand and ensure patient flow.Flu is a recurring pressure that the National Health Service faces every winter. There is particular risk of severe illness for older people, the very young, pregnant people, and those with certain underlying health conditions. The flu vaccine remains the best form of defense against influenza, particularly for the most vulnerable, and continues to be highly effective at preventing severe disease and hospitalisation.

Whether his Department has undertaken an equality impact assessment for the covid-19 autumn vaccination eligibility criteria for households containing clinically extremely vulnerable people.

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI).In line with JCVI advice, the autumn 2025 programme is focussed on targeted vaccination of those aged 75 years old and over, residents in care homes for older adults, and individuals who are immunosuppressed. These are the groups who continue to be at higher risk of serious disease, including mortality.Equality Impact Assessments were undertaken to inform the development of the COVID-19 autumn 2024 and autumn 2025 vaccination campaigns and eligibility criteria.

What assessment he has made of the potential impact of excluding (a) household members and (b) carers from eligibility for covid-19 vaccinations on clinically extremely vulnerable people.

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, involving hospitalisations and deaths, arising from COVID-19.In its advice for autumn 2024, the JCVI advised that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccine against transmission of infection from one person to another is expected to be extremely limited. Therefore, the indirect benefits of vaccination, namely vaccinating an individual such as a carer or household member to reduce the risk of severe disease in other people, are less evident now compared with previous years. Accordingly, in line with JCVI advice, carers were not eligible for a COVID-19 vaccination in autumn 2024.In line with the JCVI advice, the autumn 2025 programme is focused on targeted vaccination of the oldest adults, namely those aged 75 years old and over, residents in care homes for older adults, and individuals who are immunosuppressed. These are the groups who continue to be at higher risk of serious disease, including mortality. Any carer or household member who is eligible for vaccination through age or immunosuppression is encouraged to take up the offer of vaccination.

What steps he is taking to help prevent patients being treated in (a) corridors, (b) converted office spaces, (c) gyms and (d) other inappropriate spaces in winter 2025-26.

We are doing everything we can as fast as we can to tackle and eliminate corridor care. The Government is determined to get the National Health Service back on its feet, so patients can be treated with dignity. Our Urgent and Emergency Care Plan, published in June 2025, set out the steps we are taking to ensure that patients will receive better, faster, and more appropriate emergency care this winter, backed by a total of nearly £450 million of funding. This includes a commitment to publish data on the prevalence of corridor care. We have been taking key steps to ensure that the health service is prepared for the colder months. This includes taking actions to try to reduce the demand pressure on accident and emergency departments, increase vaccination rates, and offer health checks to the most vulnerable, as well as stress-testing integrated care board and trust winter plans to confirm they are able to meet demand and support patient flow.

What steps his Department is taking to inform patients (a) with chronic autoimmune conditions and (b) on immunosuppressive therapy of their eligibility for covid boosters in winter 2025-26; and what steps the NHS plans to take to help ensure such patients are protected.

NHS England, in partnership with the UK Heath Security Agency and the Department, has developed a suite of communications resources to encourage eligible people to get their autumn and winter vaccinations. As part of this, NHS England has produced a variety of posters and digital-screens, as well as a factsheet specifically designed for pharmacies to support conversations with individuals about eligibility for a COVID-19 vaccine.The COVID-19 vaccine is offered to those in the population most vulnerable to serious outcomes from COVID-19 and who are therefore most likely to benefit from vaccination. For autumn and winter 2025/26, the COVID-19 vaccination is offered to:- residents in a care home for older adults;- all adults aged 75 years old and over; and- persons aged six months and over who are immunosuppressed, as defined in tables three and four of the COVID-19 chapter of the Green Book, which is available at the following link: https://assets.publishing.service.gov.uk/media/68b5be03536d629f9c82a97d/Green-book-chapter-COVID-19_1_9_25.pdf.

What guidance NHS England has issued on covid booster vaccination for patients who are (a) immunosuppressed and (b) on long-term steroid therapy; and what steps his Department is taking to help ensure clinically vulnerable people are offered protection against (i) Stratus and (ii) other circulating covid variants.

The COVID-19 vaccine is offered to those in the population most vulnerable to serious outcomes from COVID-19 and who are therefore most likely to benefit from vaccination. For autumn and winter 2025/26, the COVID-19 vaccination is offered to:- residents in a care home for older adults;- all adults aged 75 years old and over; and- persons aged six months and over who are immunosuppressed, as defined in tables three and four of the COVID-19 chapter of the Green Book, which is available at the following link: https://assets.publishing.service.gov.uk/media/68b5be03536d629f9c82a97d/Green-book-chapter-COVID-19_1_9_25.pdf.NHS England, in partnership with the UK Heath Security Agency and the Department, has developed a suite of communications resources to encourage eligible people to get their autumn and winter vaccinations. As part of this, NHS England has produced a variety of posters and digital-screens, as well as a factsheet specifically designed for pharmacies to support conversations with individuals about eligibility for a COVID-19 vaccine.National invitations are designed to supplement local invitations, to ensure the National Health Service reaches as many people as possible who may be eligible. For COVID-19 vaccinations, everyone aged five to 74 years old whose NHS record suggests they may be immunosuppressed due to a medical condition or treatment, and all those eligible by age, are contacted.Eligible people are able to book via the National Booking Service or by calling 119. For those that are uncertain, they can book an appointment and discuss their eligibility with a clinician at the appointment.

Whether his Department plans to publish a winter preparedness analysis for 2025-26 defining eligibility for covid boosters.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert committee which reviews the latest data on COVID-19 risks, vaccine safety, and effectiveness and advises the department on the approach to vaccination and immunisation programmes. The JCVI published advice for future COVID-19 vaccination campaigns in autumn 2025 and spring 2026 in November 2024, and published advice for autumn 2026 and spring 2027 in July 2025. The Government accepted JCVI advice for autumn 2025 in June 2025. The Government is considering the JCVI’s advice for 2026 and spring 2027 carefully and will respond in due course.The primary aim of the national COVID-19 vaccination programme remains the prevention of serious disease, involving hospitalisations and deaths, arising from COVID-19. The JCVI assessment indicates that the oldest age cohorts and individuals who are immunosuppressed are the two groups who continue to be at higher risk of serious disease.Therefore, in autumn 2025, a COVID-19 vaccination is being offered to:- adults aged 75 years old and over;- residents in a care home for older adults;- individuals aged six months and over who are immunosuppressed, as defined in the ‘immunosuppression’ sections of tables 3 or 4 in the COVID-19 chapter of the UK Health Security Agency Green Book.The National Health Service is preparing earlier and more robustly for winter this year, with rigorous stress testing of local plans, closer working with local partners, and a far earlier kick-off of winter preparations. Vaccinations have been ramped up across the board for flu, COVID-19 and respiratory syncytial virus so families can protect themselves and others. This includes the surge capacity and escalation plans in place across all NHS and urgent care services. As set out in the 2025/26 Urgent Emergency Care Plan, the NHS is focusing on improvements that will see the biggest impact on urgent and emergency care performance this winter. The 2025/26 Urgent Emergency Care Plan is available at the following link:https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/

What steps his Department is taking to prepare for potential flu outbreaks in winter 2025-26.

We have done more than ever to prepare for winter this year with the development and better testing of winter plans. This includes surge capacity and escalation plans for urgent and emergency care.The flu vaccination programme began on 1 September 2025 for children and pregnant women. Adults aged over 65 years old, those with long term health conditions, and frontline health and social care workers will start from 1 October 2025. Further details of the plans for this year, including actions to reduce the effects of flu on demand for services, are set out in the Urgent and Emergency Care Plan for 2025/26, which is available at the following link: https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/ On 16 September, the Secretary of State addressed a gathering of Chief Executives and undertook a joint visit with the NHS England Chief Executive to set out how winter preparations were being strengthened. A further meeting with Chief Executives on 3 November also focused on winter planning.

What the conclusive findings were of the Government-funded psilocybin trial that concluded in February 2024.

The National Institute for Health and Care Research (NIHR) Clinician Scientist Fellowship titled ‘A Feasibility RCT of Single-Dose Psilocybin in Unipolar Depressive Disorder Resistant to Standard Treatments’ is shown on the NIHR Funding and Awards website as concluding in February 2024. The progress of this award was significantly delayed by the COVID-19 pandemic. The results are therefore not yet available and are due to be released in 2026.The main aim of this award is to investigate the feasibility of conducting a trial in this patient group and to contribute towards the design of a more definitive study. The award has resulted in the creation of the Psychoactive Trials Group at King’s College London, which is one of the world’s most experienced clinical research teams in this emerging area of treatment.

What assessment he has made of the potential impact of adult social care on supporting people of working age into the labour market.

Adult social care plays a vital role and directly supports people of working age to enter, remain in, or return to employment, and ultimately to maintain people’s independence. By ensuring individuals receive the right care in the right place at the right time, they are better able to contribute to society through employment, volunteering, or other forms of participation. To support working aged people into the labour market, earnings from employment are specifically disregarded from financial assessments, with further information available at the following link:https://www.legislation.gov.uk/uksi/2014/2672/regulation/14This is to ensure that working aged adults who are in employment are able to retain their earnings in full, and supplement their income, in addition to retaining the Minimum Income Guarantee (MIG) after being charged for their social care.The Government also recognises the importance of supporting unpaid carers. Access to appropriate support, such as respite care, is important to help carers maintain their own wellbeing and avoid burnout, which can otherwise lead to withdrawal from the workforce. To support this, we are committed to reviewing the implementation of Carer’s Leave and examining the benefits of introducing paid Carer’s Leave.

What discussions he has had with Baroness Casey on how sector stakeholders can engage with the commission on adult social care.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, engages with Baroness Louise Casey regularly on a number of issues, including adult social care.On 8 September, my Rt. Hon. Friend attended cross-party discussions, chaired by Baroness Casey, with representatives from political parties.Over the coming months, the commission will start a national conversation by inviting members of the public, people drawing on care and support, and organisations to submit evidence and to share their stories and ideas for improvement of the existing adult social care system. The commission will set out more details in due course.